Tiger Pharma today "knockthegong", the success of the "A-H" stock strategic layout.

On August 7, 2020, the author was informed that Tyger Pharma officially landed on the Hong Kong Stock Exchange today and successfully realized the strategic layout of the "A-H" unit.
it is worth mentioning that Tiger Pharma is also following the drug Mingkang and Kanglong into, another on the mainland stock exchange and the Hong Kong Stock Exchange listed at the same time CRO enterprises.
public information shows that Tyger Pharma was founded in 2004.
it is understood that the clinical CRO track was not crowded at that time, Tiger Pharma with hard strength quickly established a foothold in the field, and by the capital of attention.
for example, Qiming Ventures invested $7 million in Tag Pharma in two phases in June 2008 and March 2010.
August 17, 2012, Tiger Pharma officially landed on the GEM, the price of 37.88 yuan per share, the listing day closed at 50 yuan, up 32%, the market value of nearly 2.7 billion.
at present, Tyger Pharmaceuticalhas has become a leading clinical CRO enterprises in China, mainly for domestic and foreign pharmaceutical and medical device innovation enterprises to provide innovative drugs, medical devices and biotechnology-related products of the whole process of clinical research professional services. In the eight years since the
listing, Tyger Pharma's share price has doubled, to a 15-fold increase, with a market capitalization of 80.49 billion yuan.
the public offering, Tiger Pharma issued a total of 107 million shares at HK$100, raising HK$10.7 billion.
Tiger Pharmaceuticals shares opened at HK$119 at midday and closed at HK$114.6 by midday. according to the
prospectus, in the three years from 2017 to 2019, Tag Pharma completed more than 400 clinical research and development outsourcing projects, serving 1,570, 1,788 and 1,898 clients, respectively.
in recent years, The salary and gross profit of Tag Pharma have also been increasing.
2017 to 2019 and the first quarter of 2020, Tyger Pharmaceuticals' revenue reached 1,683 million yuan, 2.299 billion yuan, 2.803 billion yuan and 655 million yuan, respectively;
, clinical CRO is a staff-intensive industry, the number of personnel is the core factor of production of clinical CRO services, the company's total number of employees has increased rapidly since 2012.
data show that as of December 31, 2019, The pharma's clinical team will have nearly 2,500 people, including 840 clinical inspectors, 1,490 clinical research coordinators and 100 patient recruits.
it is understood that more than 80% of the more than 500 GCP-registered clinical trial institutions in China have established a partnership with Tyger Pharma.
the prospectus mentioned that the proceeds from the IPO will be used to expand and enhance operational capacity or capacity to meet growing demand in overseas markets.
also finance potential acquisitions or investments to supplement existing business, repay borrowings, recruit technical and scientific professionals, and working capital and general corporate use.
on the CRO industry to which Tag Pharmaceuticals belongs, with the promotion of policies such as volume procurement, consistency evaluation, medical insurance payment, innovation pharmaceutical industry will usher in good development opportunities, because of the high risk of new drug research and development, high cost, long-term characteristics, known as "water seller" CRO industry is also optimistic.
the current growth rate of the global drug research and development outsourcing service market is significantly higher than the 3.5% growth rate of the innovative drug market, and the growth rate of the domestic drug research and development/production outsourcing service market is also significantly higher than the 4.8% growth rate of the innovative drug market.
data show that the global CRO market is expected to be $67.2 billion in 2020, with CAGR of 9.0% in five years, of which the clinical CRO market is close to $43.2 billion and the five-year CAGR is about 8.7%.
.